A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With MabThera vs no Treatment, After Induction With MabThera, Cladribine and Cyclophosphamide on Progression-free Survival in Previously Untreated Patients With Progressive B-CLL. The Trial Conducted With PALG Sites
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival in the maintenance phase
Event driven
No
Clinical Trials
Study Director
Hoffmann-La Roche
Poland: Ministry of Health
ML21283
NCT00718549
July 2009
July 2017
Name | Location |
---|